Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01576666
Title Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

colorectal cancer

pancreatic adenocarcinoma

breast cancer

glioblastoma

Advanced Solid Tumor

Therapies

Buparlisib + Sonidegib

Age Groups: adult
Covered Countries USA | ITA | ESP | DEU | CAN | BEL

Facility Status City State Zip Country Details
Cedars Sinai Medical Center SC Los Angeles California 90048 United States Details
University of California San Francisco UCSF (SC) San Francisco California 94101 United States Details
H. Lee Moffitt Cancer Center & Research Institute Moffitt 4 Tampa Florida 33612 United States Details
Dana Farber Cancer Institute Dana SC Boston Massachusetts 02215 United States Details
Mayo Clinic - Rochester Division of Hematology Rochester Minnesota 55905 United States Details
Duke University Medical Center Duke - Baker Durham North Carolina 27710 United States Details
Willamette Valley Clinical Studies Williamette Valley Cancer Eugene Oregon 97404 United States Details
Northwest Cancer Specialists Northwest Cancer Portland Oregon 97210 United States Details
Fox Chase Cancer Center FCCC Philadelphia Pennsylvania 19111-2497 United States Details
Texas Oncology Midtown Texas Oncology Dallas Texas 75251 United States Details
Sammons Cancer Center - Texas Oncology SC-2 Dallas Texas 78246 United States Details
University of Texas/MD Anderson Cancer Center SC-3 Houston Texas 77030-4009 United States Details
University of Utah / Huntsman Cancer Institute Huntsman Salt Lake City Utah 84103 United States Details
Novartis Investigative Site Parkville Victoria 3050 Australia Details
Novartis Investigative Site Wilrijk 2610 Belgium Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Ancona AN 60126 Italy Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Barcelona Catalunya 08003 Spain Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Glasgow G12 0YN United Kingdom Details
Novartis Investigative Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field